Can targeted drugs tame complex vascular anomalies? a registry seeks answers
NCT ID NCT07767877
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study gathers real-world data from medical records of patients with complex vascular anomalies treated with targeted therapies like mTOR inhibitors, MEK inhibitors, or PI3K inhibitors. Researchers will look at patient characteristics, treatment patterns, and side effects across multiple US centers. The goal is to better understand how these drugs are used in everyday practice and what outcomes patients experience.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Targeted therapies including mTOR inhibitors (sirolimus/everolimus), MEK inhibitor (trametinib), and PI3K inhibitor (alpelisib)
- What this could lead to
- This registry could help doctors understand how targeted therapies are used in real-world practice for vascular anomalies, potentially improving treatment decisions and patient care.
- What could go wrong
- As a registry study, it does not test new treatments directly. It relies on existing medical records, which may be incomplete or vary across centers, and cannot prove which treatment works best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR ANOMALIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cancer drug shows promise for rare blood vessel disorders
- Cancer drug shows promise for rare blood vessel disorders in kids and young adults
- New hope for rare vascular malformations: targeted drugs enter trial
- New registry aims to unlock secrets of rare diseases
- New drug targets root cause of rare overgrowth syndromes